TY - JOUR
AU - Lee, Seung Hwan
AB - What is already known about this subjectPotassium‐competitive acid blockers (P‐CABs), a new class of acid‐suppressive agents, are being actively developed to overcome the unmet needs of proton pump inhibitors.A novel tegoprazan modified‐release (MR) formulation, P‐CAB, may improve its efficacy by overcoming nocturnal acid breakthrough.What this study addsCombinations of tegoprazan immediate‐release (IR) and delayed‐release (DR) formulations induced sustained gastric acid suppression for 24 h, including at night‐time.The combinatorial tegoprazan in the IR and DR 1:1 ratio formulation could be an ideal formulation to substitute for the conventional IR formulation.INTRODUCTIONGastroesophageal reflux disease (GERD) manifests as mucosal damage caused by the abnormal reflux of gastric contents into the oesophagus, oral cavity or lungs.1,2 Generally, gastric acid suppression, which essentially aims at maintaining intragastric pH above 4, is key to management of GERD. Consequently, proton pump inhibitors (PPIs) have been developed and are widely used for treating patients with GERD; however, there are some concerns about them, such as their slow onset of action and the frequent occurrence of nocturnal acid breakthrough (NAB), defined as the presence of an intragastric pH value lower than 4 for more than 1 h during the night, in the treated patients.3–7To overcome these unmet needs, potassium‐competitive acid blockers (P‐CABs), 
TI - Pharmacokinetic and pharmacodynamic exploration of various combinations of tegoprazan immediate and delayed‐release formulations
JF - British Journal of Clinical Pharmacology
DO - 10.1111/bcp.15784
DA - 2023-09-01
UR - https://www.deepdyve.com/lp/wiley/pharmacokinetic-and-pharmacodynamic-exploration-of-various-ptftcRP2H2
SP - 2877
EP - 2887
VL - 89
IS - 9
DP - DeepDyve
ER -